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a b s t r a c t
Human adenovirus can establish latent infections in lymphoid tissues in vivo and persistent, infections in
cultured lymphoid cell lines. During lytic infection, adenovirus expresses microRNAs (miRNAs) derived
from the viral non-coding RNAs VAI and, especially, VAII. Here, we demonstrate that persistently
adenovirus-infected human BJAB cells also produce adenovirus-derived miRNAs primarily derived from
the viral VAII RNA, which contributes 2.7% of all RNA-induced silencing complex (RISC)-associated
RNAs. However, our data indicate that the 5′ end of the predominant VAII-derived viral RNA, and hence
its seed sequence, differs fromwhat has been previously reported. Our data demonstrate that adenovirus
expresses viral miRNAs in chronically infected lymphoid cells and raise the possibility that these may
contribute to the maintenance of the latently adenovirus-infected lymphoid cells previously observed in
mucosal-associated lymphoid tissues in vivo.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Adenoviruses (AdVs) are double-stranded DNA viruses with an
36 kb genome bearing inverted terminal repeats. In addition to a
range of viral proteins, AdVs also encode short non-coding RNAs,
called virus associated or VA RNAs, that are transcribed by cellular
RNA polymerase III (pol III) (Söderlund et al., 1976; Wu, 1978).
Different AdV serotypes express one or two VA RNAs. While VAI is
found in all AdV serotypes, VAII is only detected in a subset of
AdVs, including most C serotypes (Ma and Mathews, 1996). Both
VA RNAs are 160 nucleotides (nt) in length and both fold into
similar compact stem–loop structures. This RNA structure can be
divided into three regions: the terminal stem (including the paired
5′ and 3′ ends), an apical stem and a structured central domain
(Ma and Mathews, 1993, 1996). The major function of VAI is
believed to be the competitive inhibition of the cellular
RNA-dependent protein kinase PKR, an interferon-inducible ser-
ine–threonine kinase that is activated in infected cells by double-
stranded RNAs as part of the antiviral response (Kitajewski et al.,
1986; O’Malley et al., 1986). VAI may also stabilize the association
of ribosomes with AdV mRNAs, which leads to increased levels
of late viral protein synthesis (O’Malley et al., 1989). Inactivation
of VAI causes a 10–20-fold decrease in viral growth in culture
(Bhat et al., 1985; Thimmappaya et al., 1982). When both VAI and
VAII RNAs are deleted, viral growth decreases 60-fold (Bhat and
Thimmappaya, 1985).
MicroRNAs (miRNAs) are a large family of 22-nt regulatory
RNAs capable of posttranscriptionally downregulating the expres-
sion of target mRNAs (reviewed in Skalsky and Cullen (2010)).
They are typically transcribed as part of one arm of an 80-nt RNA
stem-loop located in a longer capped, polyadenylated transcript,
referred to as a primary miRNA (pri-miRNA). The stem-loop is
bound by the RNase III enzyme Drosha and cleaved 22 bp away
from the loop to generate an 60-nt RNA hairpin, bearing a 2-nt
3′ overhang, referred to as the precursor miRNA (pre-miRNA)
intermediate. The pre-miRNA is bound by Exportin5 (Exp5) and
exported to the cytoplasm where the pre-miRNA is recognized by
Dicer, a second RNase III enzyme. Dicer cleaves 22 bp from the
base of the pre-miRNA to release the terminal loop and generate a
short RNA duplex. One strand of this duplex is incorporated into
the RNA-induced silencing complex (RISC), which minimally
consists of the mature miRNA and a cellular Argonaute (Ago)
protein. The mature miRNA then guides RISC to complementary
target sites located predominantly in the 3′ UTRs of target mRNAs,
resulting in translational repression and/or mRNA degradation.
VA RNAs can inhibit host cell miRNA expression and function in
AdV infected cells (Andersson et al., 2005; Aparicio et al., 2006;
Lu and Cullen, 2004). VA RNAs have a stem–loop structure that is
similar to that of pre-miRNAs and they are subjected to similar
processing. In particular, both pre-miRNAs and VA RNAs are
exported to the cytosol by Exp5 and both are also processed by
Dicer. However, Dicer processing of VAII and, especially, VAI is
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inefﬁcient and VAI indeed functions as a competitive inhibitor of
Dicer function (Andersson et al., 2005; Lu and Cullen, 2004). As a
result, less than 1% of VAI is processed by Dicer in lytically AdV
infected cells. Nevertheless, because the VA RNAs are expressed at
very high levels—up to 108 copies of VAI per AdV-infected cell—
these VAI and VAII RNA-derived Dicer cleavage products accumu-
late to signiﬁcant levels. Importantly, these short RNAs are
incorporated into RISC (Aparicio et al., 2006; Xu et al., 2007)
and can comprise up to 80% of the RISC-associated small RNAs late
in the lytic AdV replication cycle (Xu et al., 2007). Overall, earlier
reports therefore suggest that the observed inhibition of cellular
miRNA biogenesis and function by the AdV VA RNAs during lytic
replication results from the progressive saturation or inhibition of
critical factors required for miRNA biogenesis and function, includ-
ing Exp5, Dicer and the Ago proteins. Nevertheless, the small RNAs
derived from the AdV VA RNAs that are incorporated into RISC can
function as miRNAs and, as a result, both AdV infection and the
ectopic expression of VAI can speciﬁcally inhibit the expression of
reporter genes containing artiﬁcial target sequences (Andersson
et al., 2005; Aparicio et al., 2006). VA RNAs have also been
reported to downregulate the expression of cellular mRNAs bear-
ing complementary target sequences in their 3′ UTR (Aparicio
et al., 2010).
AdV is a pathogenic virus responsible for various diseases in
human beings. The adenovirus species C serotypes (subtypes 1, 2,
5 and 6) are commonly associated with upper and lower respira-
tory tract infections in children (Avila et al., 1989; Edwards et al.,
1985). Following primary infection, species C adenoviruses often
remain detectable in the host (Fox et al., 1969, 1977). It has been
reported that replication-competent AdVs can persist for pro-
longed periods in mucosal-associated lymphoid tissues, notably
tonsils and adenoids, in individuals lacking any disease symptoms
(Evans, 1958; van der Veen and Lambriex, 1973). Studies have also
reported the detection of non-replicating adenoviral DNA in
tonsils (Garnett et al., 2002; Neumann et al., 1987), which have
been subsequently shown to reﬂect true latent AdV infections in
lymphoid tissues (Garnett et al., 2009).
Previous studies looking at the effect of AdV VA RNAs on
miRNA function in infected cells have generally used transformed
cell lines undergoing lytic infection. However, a number of groups
have reported success at persistently infecting human lymphoid
cell lines with AdVs, and these infections appeared to be largely
nonlytic, at least over the medium term (Lavery et al., 1987;
McNees et al., 2004; Silver and Anderson, 1988). Recently, T- and
B-lymphocyte derived cell lines persistently infected with AdV for
extended periods of time have been described (Zhang et al., 2010).
In this study, we report the characterization of viral miRNAs in
human lymphoid cells persistently infected with AdV.
Results
We analyzed two human lymphoid cell lines in the present
study: BJAB (B cells) and KE37 (T cells). The cell lines were infected
with adenovirus (subtype 5) and maintained in culture for over 60
days. We then conducted a limiting dilution assay to determine
the proportion of viral DNA-bearing cells in cell lines chronically
infected with AdV. From the Poisson considerations, the dilution at
which viral DNA is detected in 63% of the wells provided an
average of one viral DNA-positive cell per well. The data shown in
Fig. 1 were ﬁt by logistic regression to determine this value. For
BJAB cell lines, approximately 1 in 1.6 cells (63%) were deter-
mined to contain AdV DNA. KE37 cell lines harbor viral DNA in
approximately 1 in 2.9 cells (34%).
Next, we tested whether the AdV VA RNAs are expressed in this
chronic infection model. We compared expression levels of VA
RNAs and several early (E) and late (L) viral transcription units.
As shown in Fig. 2, VA RNAs are expressed at levels signiﬁcantly
higher than transcription units for the viral early genes and at
levels comparable to late mRNAs. However, differences of reverse
transcription efﬁciency among RNA transcripts were not deter-
mined in this experiment as we used viral genomic DNA, not RNA,
as a standard. Since VA RNAs are highly structured, the reverse
transcription efﬁciency of VA RNAs might be lower than for
the viral mRNAs. Therefore, these data likely underestimate the
relative expression level of VA RNAs. Nevertheless, we can con-
clude that VA RNAs are expressed in our chronic AdV infection
model.
Previously, it was reported that persistently AdV infected BJAB
cell cultures constitutively produce low but detectable levels of
infectious virus, 2 infectious virions per cell on average (Zhang
et al., 2010), and this is consistent with the low but detectable
levels of AdV late gene mRNAs detected in these persistently
infected B cells by RT-PCR (Fig. 2). On the other hand, and as
previously reported (Zhang et al., 2010), these cells grow normally
and show no evidence of viral cytopathic effect, thus suggesting
that only a small minority of cells are, in fact, undergoing lytic AdV
infection. To address this question further, we used high through-
put quantitative ﬂuorescent microscopy to identify cells that
express either the AdV hexon (L3) or 100 K assembly (L4) protein,
both of which are AdV late proteins. In BJAB cells, we detected the
L3 protein in 0.7770.12% of the cells, while L4 was detected in
0.7570.10% of the cells. We therefore conclude that these persis-
tently AdV infected BJAB cultures are, in fact, a mixture of
uninfected cells (37%), latently AdV infected cells (62%) and
productively AdV infected cells (0.8%). Similarly, in the persis-
tently AdV infected KE37 culture, we determined that 0.3270.05%
of the cells were positive for expression of the late AdV L3 protein
while 0.3870.05% were positive for L4. The KE37 culture is
Fig. 1. Determination of AdV DNA levels in persistently infected lymphoid cells.
A master lysate plate was prepared by diluting persistently AdV-infected BJAB or
KE37 cells at 1000, 100, 10, 1, and 0.1 cells per well and twelve wells for each
dilution were tested for AdV DNA y a nested PCR assay. The percentage of positive
wells was plotted with a best-ﬁt three-parameter logistic ﬁt constrained between
0% and 100%.
Fig. 2. Detection of VA RNAs and other viral transcription units. Relative expression
levels of various AdV RNAs in the persistently AdV-infected BJAB cells were
determined by qRT-PCR and then normalized to VAI. RT indicates samples with
reverse transcription and no-RT indicates negative controls prepared without
reverse transcriptase. Error bars indicate standard deviation of 3 independent
experiments. Black bars indicate VA RNAs. Light gray and dark gray bars represent
transcription units for AdV early (E) and late (L) genes, respectively.
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therefore also a mixture of uninfected cells (66%), latently
infected cells (34%) and productively AdV infected cells (0.3%).
We next asked whether we could detect AdV-derived small
RNAs in these AdV infected BJAB and KE37 cultures using deep
sequencing of small RNAs. This technique yielded 12,803,374 reads
for the AdV-infected BJAB cells, and 13,562,047 reads for the KE37
cells, that mapped either to the AdV or human genome. Only a
small proportion of small RNA reads were derived from the AdV
genome (1.1% for BJAB and 0.1% for KE37). As expected, the
majority of reads mapping to the human genome were cellular
miRNAs and the length distribution for small RNAs that map to the
human genome shows an obvious peak at 22 nt, as expected for
miRNAs (Fig. 3A and B). As for AdV speciﬁc reads, the observed
length distribution also shows a strong peak at 22 nt, which is
inconsistent with the idea that these are predominantly viral RNA
degradation products. Reads that mapped to neither the human
nor viral genome (unmapped reads) showed no peak in length
distribution. Therefore, the discrete size observed for reads that
mapped to the AdV genome suggests that there is a mechanism to
generate small RNAs of speciﬁc length from the viral genome.
As expected, most sequences that mapped to the AdV genome
were derived from the VA RNAs, and three to ﬁve times more
reads were derived from VAII compared to VAI (Fig. 3C). These
results are consistent with an earlier study showing that VAII is
preferentially digested by Dicer (Xu et al., 2007). Figs. 4 and 5
present the site-by-site deep sequence coverage of the VA RNAs.
For both VAI and VAII, the terminal stem regions show higher
coverage than the other regions. Small RNAs were derived from
both the 5′ and 3′ ends of VAI, while the 3′ end of VAII showed a
much higher coverage than the 5′ end. We next tallied read counts
for each small RNA based on their 5′ end (Figs. 6 and 7). Most
reads derived from near the 5′ end of VAI start from the known
5′ end of VAI (position 1, from here on we deﬁne this small RNA as
“smRNA-VAI1”. This corresponds to position 10620 of the AdV
reference genome, AC_000008). Interestingly, two positions (posi-
tions 128 and 137) were identiﬁed as starting positions for small
RNAs derived from near the 3′ end of VAI (smRNA-VAI128 and
smRNA-VAI137 respectively). The majority of the smRNA-VAI137
reads are 22 nt in length and these small RNAs end at the known
3′ end of VAI (position 158). Most smRNA-VAI128 reads are 31 nt
in length and, hence, also end at the known 3′ terminus of VAI.
While smRNA-VAI128 was barely detectable in KE37 cells, we note
that we might have missed this population because of our experi-
mental procedure. We performed size-fractionation to isolate small
Fig. 3. Small RNA deep sequencing. (A) Length distribution of reads mapped to the
AdV or human genome, and unmapped small RNA reads, (B) breakdown of reads
mapped to human genome according to the class of RNA that they originate from,
and (C) Breakdown of reads mapped to the AdV genome according to origin.
Fig. 4. Site-by-site coverage of VAI by small RNAs. (A) A schematic secondary
structure for VAI is shown. Red, yellow and green indicate the terminal stem, the
central domain and the apical region, respectively. (B) The percentage of site-by-
site coverage relative to total coverage (both human and AdV genome) is plotted.
The X-axis shows positions from the 5′ end to 3′ end of VAI. Open dots reﬂect the
result of deep-sequencing the total small RNA population while ﬁlled gray dots
represent reads obtained using RNA isolated by RIP against Ago2 (only for BJAB
cells). Regions of origin in VAI are speciﬁed by colors that correspond to panel A.
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RNAs of between 17 and 30 nt in length. Therefore, smRNAVAI-
128 (31 nt in length) would be located at the edge of the
fractionation border. We note that previous analysis of RISC-
associated VAI-derived small RNAs in lytically AdV-infected cells
found that these derived from the 3′ end of VAI with start sites at
position 137 and 138 (Sano et al., 2006; Xu et al., 2007), with the
latter more prevalent, while we saw very few small RNA reads
starting at position 138 in VAI in the persistently infected BJAB cells.
With regard to VAII, the small number of reads derived from
near the 5′ end again started from position 1 (smRNA-VAII1; this
corresponds to position 10876 of the AdV reference genome).
Three sites were identiﬁed as starting positions for major small
RNAs derived from near the 3′ end of VAII, namely smRNA-
VAII136, smRNA-VAII137 and smRNA-VAII138, all of which termi-
nated at the known 3′ end of VAII. As shown by site-by-site
coverage in Fig. 5, smRNA-VAII1 (derived from the 5′ end) is much
less prevalent than the small RNAs derived from 3′ end of
VAII. smRNA-VAII136, smRNA-VAII137 and smRNA-VAII138 are
expressed at equivalent levels. Their lengths are mostly between
20 and 23 nt, supporting previous reports that small RNAs are
generated by cleavage of VAII by Dicer, which usually cleaves
dsRNAs 22 bp from the end (Tsutsumi et al., 2011).
We next addressed whether these small viral RNAs are incor-
porated into RISC. We performed an immunoprecipitation using a
monoclonal antibody speciﬁc for the RISC component Ago2 and
then deep-sequenced all associated small RNAs (RIP-seq) from
BJAB cells. Sequence coverage for both VAI and VAII increased after
RIP, especially for small RNAs derived from the 3′ end region
(Figs. 4 and 5). In the case of VAI, the representation of smRNA-
VAI137 remained fairly constant between the total and RISC-
associated small RNA libraries, contributing 0.035% of both
(Fig. 6). In contrast, the 31-nt smRNA-VAI128 was actually
detected at higher levels in RISC, when compared to the total
small RNA library, increasing from 0.047% to 0.18%. This is
surprising, given that its length is beyond that normally seen for
miRNAs. Similarly, RISC-association efﬁciency was found to differ
among the similar, VAII-derived smRNA-VAII136, smRNA-VAII137
and smRNA-VAII138 (Fig. 7). Only smRNA-VAII136 was preferen-
tially loaded into RISC (5-fold enrichment over the total small RNA
population, 0.47% versus 2.49%). In contrast, loading of the two
other small viral RNAs (smRNA-VAII137 and smRNA-VAII138)
decreased by 3- to 5-folds when compared to their prevalence in
the total small RNA population. In contrast to a previous report
that found smRNA-VAII138 to be the dominant RISC-associated
VAII-derived small RNA in lytically infected 293 cells (Xu et al.,
2007), we observed much higher levels of smRNA-VAII136 in
persistently infected BJAB cells (Fig. 7). As the 5′ end of a miRNA
Fig. 5. Site-by-site coverage of VAII by small RNAs. The ﬁgure is for VAII and was
generated exactly as described for VAI in Fig. 4.
Fig. 6. Small RNAs derived from VAI. Each bar represents both the expression level
and origin of each VAI-derived small RNA in either the total small RNA library or
the RISC-associated small RNA library. The percentage contribution of each small
RNA population to the total number of reads obtained is shown to the left of each
bar. Dashed lines indicate the 5′ nucleotide of each RNA.
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determines the identity of the miRNA seed sequence (positions 2 to
8 from the 5′ end), which plays a major role in determining miRNA
target speciﬁcity (Bartel, 2009), this difference is signiﬁcant.
Discussion
The goal of this research was to examine whether AdV produces
viral miRNAs in latently infected lymphoid cells that might play a
role in facilitating latency and/or avoiding immune elimination. For
this purpose, we analyzed cultures of BJAB B cells and KE37 T cells
that had been previously reported to maintain a persistent AdV
infection (Zhang et al., 2010). Our analysis of these cells, however,
revealed that they in fact represent a mixed population of latently
AdV infected and uninfected cells, with a small proportion (o1%) of
cells that are in fact undergoing productive AdV infection. Never-
theless, we performed a deep sequencing analysis of the small RNA
populations in these AdV infected cells and were able to identify a
readily detectable population of AdV encoded miRNAs that are
derived from the VAII non-coding RNA and efﬁciently incorporated
into RISC (Fig. 7). We also detected two RISC-associated AdV
miRNAs that were derived from the viral VAI RNA, though these
were, as previously reported (Xu et al., 2007), expressed at a much
lower level (Fig. 6). The AdV-derived small RNAs detected in this
analysis are therefore similar to what has been previously reported,
with the exception that the dominant, RISC-associated AdV miRNA
was found to initiate at position 136 in VAII, not position 138 as
previously reported (Xu et al., 2007). This difference is not due to
sequence differences in VAII, which is identical in the AdVs used in
both studies. This difference could therefore arise from the different
cell lines analyzed (293 cells versus lymphoid cells), from biases
present in the deep sequencing protocols used or because the 293
cells were undergoing lytic replication while the lymphoid cells
analyzed here were largely latently AdV infected. It is important to
note, however, that we do not in fact know the relative contribution
of the latently AdV infected (62% of total BJAB cells) versus the
lytically AdV cells (0.8%) to the small RNA cDNA library that we
prepared and it remains possible that the majority of viral small
RNA are, in fact, derived from the latter. It is clear, however, that not
all of the viral miRNAs are derived from the productively infected
cells as these viral miRNAs contributed 3% of the total RISC-
associated miRNA population yet only 0.8% of the cells in the BJAB
culture were found to be productively infected with AdV.
In conclusion, our data are fully consistent with the idea that AdV
is able to express viral miRNAs in persistently infected lymphoid
cells, including those detected in vivo in mucosal-associated lym-
phoid tissues, and raise the possibility that these viral miRNAs play
an important role in facilitating persistent AdV infection, as pre-
viously also proposed for the viral miRNAs expressed by several
herpesvirus species (Dölken et al., 2010; Murphy et al., 2008;
Umbach et al., 2008).
Materials and methods
Cell lines and virus
B-cell derived BJAB (EBV-negative Burkitt's lymphoma) cells and
T-cell derived KE37 cells were grown in RPMI medium supplemen-
ted with 10% fetal calf serum.
Species C AdV subtype 5 virus Ad5dl309 was obtained from Tom
Shenk (Princeton University). Ad5dl309 lacks the genes for the viral
E3 RIDα, RIDβ and 14.7 K proteins. Infection of lymphoid cell lines
with AdV was performed as described previously (McNees et al.,
2004; Zhang et al., 2010). The experiments described were per-
formed 66–211 days after infection.
Limiting dilution analysis
Detailed methods were described previously (Zhang et al., 2010).
Brieﬂy, a master lysate plate was prepared by diluting infected cells
at 1000, 100, 10, 1, and 0.1 cells per well with uninfected cells so that
the total equaled 1105 cells/well. Twelve wells for each dilution
were tested by PCR for viral genomes. The percentage of viral DNA-
positive wells was plotted with a best-ﬁt three-parameter logistic ﬁt
constrained between 0% and 100%. The number of cells added per
well that yield 63% positive wells corresponds to one adenovirus
DNA-positive cell per well.
qRT-PCR
To determine the expression level of viral RNAs, total RNA was
extracted with TRIzol (Invitrogen), then reverse transcribed to
cDNA using a High Capacity cDNA Reverse Transcription Kit with
random primers (Applied Biosystems). Viral genomic DNA was
also extracted with DNeasy Blood & Tissue Kit (QIAGEN). The
cDNAs were quantiﬁed by qPCR (POWER SYBR Green PCR Master
Fig. 7. Small RNAs derived from VAII. The ﬁgure for VAII-derived small RNAs was
generated as described for VAI in Fig. 6.
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Mix, Applied Biosystems) with standard curves of serial dilution of
viral genomic DNA. Sequence of primers is available upon request.
Small RNA deep sequencing
Total RNA was extracted using TRIzol and small RNA isolated by
size-fractionation on 15% TBE-Urea polyacrylamide gels. Small RNAs
corresponding to 17–30 nt in length were sequentially ligated to
adapters and reverse-transcribed using a TruSeq Small RNA Sample
Prep Kit (Illumina) and SSII (Invitrogen). cDNAs were ampliﬁed by
PCR (20 cycles). The number of PCR cycles was determined by pilot
experiments to ﬁnd a point at which amplicons showed logarithmic
ampliﬁcation. Deep-sequencing of the PCR products was performed
using a HiSeq2500 machine (illumina).
For RNA immunoprecipitation (RIP), cells were collected and
lysed using lysis buffer (50 mM HEPES, 150 mM KCl, 2 mM EDTA,
1 mM NaF, 0.5% NP40, 0.5 mM DTT). Lysates were incubated with
Dynabeads Protein G (Novex) conjugated with an Ago2-speciﬁc
monoclonal antibody (9E8.2, Millipore). The beads were then
repeatedly washed with PBS and then TRIzol was added to extract
bound RNA, which was subjected to small RNA deep-sequencing
as described above.
Bioinformatics
Sequence data were analyzed using the FASTX-Toolkit and
aligned with the type 5 adenovirus genome (GenBank accession
number: AC_000008) and the human genome (hg19) by Bowtie
(Langmead et al., 2009). Results of mapping were analyzed by
SAMtools and DARIO (Fasold et al., 2011; Li et al., 2009).
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